Company
Headquarters: Cambridge, MA, United States
Employees: 83
CEO: Dr. Barbara L. Weber M.D.
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $36.5 M |
| EBITDA | $-111,758,000 |
| Gross Profit TTM | $0 |
| Profit Margin | -278.55% |
| Operating Margin | -644.69% |
| Quarterly Revenue Growth | -15.30% |
Tango Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TNGX wb_incandescent